Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Medications Development for Drug Abuse Disorders

Trial Profile

Medications Development for Drug Abuse Disorders

Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Tramadol (Primary) ; Buprenorphine/naloxone; Clonidine
  • Indications Opioid abuse
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2017 Primary endpoint (Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period) has been met according to results published in the JAMA Psychiatry.
    • 21 Jul 2017 New trial record
    • 12 Jul 2017 Results published in the JAMA Psychiatry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top